» Articles » PMID: 30555413

Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability

Overview
Specialty Endocrinology
Date 2018 Dec 18
PMID 30555413
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Sex-related differences have been reported in various cancers, in particular men with lactotroph tumors have a worse prognosis than women. While the underlying mechanism of this sexual dimorphism remains unclear, it has been suggested that a lower estrogen receptor alpha expression may drive the sex differences observed in aggressive and malignant lactotroph tumors that are resistant to dopamine agonists. Based on this observation, we aimed to explore the molecular importance of the estrogen pathway through a detailed analysis of the transcriptomic profile of lactotroph tumors from 20 men and 10 women. We undertook gene expression analysis of the selected lactotroph tumors following their pathological grading using the five-tiered classification. Chromosomic alterations were further determined in 13 tumors. Functional analysis showed that there were differences between tumors from men and women in gene signatures associated with cell morphology, cell growth, cell proliferation, development, and cell movement. Hundred-forty genes showed an increased or decreased expression with a minimum 2-fold change. A large subset of those genes belonged to the estrogen receptor signaling pathway, therefore confirming the potent role of this pathway in lactotroph tumor sex-associated aggressiveness. Genes belonging to the X chromosome, such as , and , were identified as appealing candidates with a sex-linked dysregulation in lactotroph tumors. Through our comparative genomic hybridization analyses (CGH), chromosomic gain, in particular chromosome 19p, was found only in tumors from men, while deletion of chromosome 11 was sex-independent, as it was found in most (5/6) of the aggressive and malignant tumors. Comparison of transcriptomic and CGH analysis revealed four genes () located on gained regions of chromosome 19 and upregulated in lactotroph tumors from men. MATK and STAP2 are both implicated in cell growth and are reported to be associated with the estrogen signaling pathway. Our work confirms the proposed involvement of the estrogen signaling pathway in favoring the increased aggressiveness of lactotroph tumors in men. More importantly, we highlight a number of ER-related candidate genes and further identify a series of target molecules with sex-specific expression that could contribute to the aggressive behavior of lactotroph tumors in men.

Citing Articles

Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial].

Schmidt I, Vergeer R, Postma M, van den Berg G, Sterkenburg A, Korsten-Meijer A Eur J Nucl Med Mol Imaging. 2024; 52(2):660-668.

PMID: 39390132 PMC: 11732902. DOI: 10.1007/s00259-024-06947-9.


Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.

Voznyak O, Zinkevych I, Lytvynenko A, Hryniv N, Ilyuk R, Kobyliak N Rev Recent Clin Trials. 2024; 19(3):204-214.

PMID: 38561622 DOI: 10.2174/0115748871288948240325080936.


Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.

Dzialach L, Sobolewska J, Zak Z, Respondek W, Witek P Front Endocrinol (Lausanne). 2024; 15:1338345.

PMID: 38370355 PMC: 10870150. DOI: 10.3389/fendo.2024.1338345.


The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.

Dumitriu-Stan R, Burcea I, Nastase V, Ceausu R, Dumitrascu A, Cocosila L Int J Mol Sci. 2023; 24(22).

PMID: 38003353 PMC: 10671753. DOI: 10.3390/ijms242216162.


Case Report: Multiple prolactinomas in a young man with Kallmann syndrome and familial hypocalciuric hypercalcemia.

Jensterle M, Janez A, Vipotnik Vesnaver T, Debeljak M, Breznik N, Trebusak Podkrajsek K Front Endocrinol (Lausanne). 2023; 14:1248231.

PMID: 37964948 PMC: 10642931. DOI: 10.3389/fendo.2023.1248231.


References
1.
Kimura I, Honda R, Okai H, Okabe M . Vascular endothelial growth factor promotes cell-cycle transition from G0 to G1 phase in subcultured endothelial cells of diabetic rat thoracic aorta. Jpn J Pharmacol. 2000; 83(1):47-55. DOI: 10.1254/jjp.83.47. View

2.
Vidal S, Kovacs K, Horvath E, Scheithauer B, Kuroki T, Lloyd R . Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 2001; 438(6):595-602. DOI: 10.1007/s004280000373. View

3.
Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H . Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001; 85(5):713-20. PMC: 2364114. DOI: 10.1054/bjoc.2001.1974. View

4.
Lloyd R, Scheithauer B, Kuroki T, Vidal S, Kovacs K, Stefaneanu L . Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas. Endocr Pathol. 2002; 10(3):229-235. DOI: 10.1007/BF02738884. View

5.
Ulbricht U, Brockmann M, Aigner A, Eckerich C, Muller S, Fillbrandt R . Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol. 2003; 62(12):1265-75. DOI: 10.1093/jnen/62.12.1265. View